Business
KRTL Holding Group Inc. Announces Milestone Achievement: FDA Registration of Industria Químico Farmaceutica SIGMA CORP. S.R.L.’s Federal Establishment Identifier
KRTL Holding Group Inc. Announces Milestone Achievement: FDA Registration of Industria Químico Farmaceutica SIGMA CORP. S.R.L.’s Federal Establishment Identifier.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"\n Lakewood, CO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. proudly announces the successful registration of Industria Químico Farmaceutica SIGMA CORP. S.R.L. (SIGMA), a premier Bolivian pharmaceutical company, with the United States Food and Drug Administration’s (FDA) Federal Establishment Identifier (FEI). This pivotal milestone highlights the collaboration between KRTL and Sigma in advancing regulatory readiness and enabling access to the highly regulated U.S. market. Bolivia, renowned for its rich biodiversity and abundant natural resources, offers a wealth of untapped opportunities in the pharmaceutical sector. The partnership between KRTL and SIGMA shines a spotlight on Bolivia’s growing potential as a hub for pharmaceutical innovation and manufacturing. As noted by the U.S. Department of Commerce, “Bolivia presents untapped potential in the development of pharmaceutical manufacturing and export capabilities, offering a promising avenue for partnerships and investments.” This achievement paves the way for Bolivian pharmaceutical products to make their mark on the global stage. SIGMA, a recognized leader in Bolivia’s pharmaceutical industry, embodies the country’s aspirations to elevate its manufacturing and export capabilities. Through this collaboration, KRTL and SIGMA aim to unlock new possibilities for leveraging Bolivia’s unique natural resources to produce high-quality pharmaceutical products that meet stringent U.S. regulatory standards. “This registration represents a transformative step in positioning Bolivian-manufactured pharmaceuticals for global opportunities,” stated Cesar Herrara, Chief Executive Officer of KRTL Holding Group Inc. “Bolivia’s wealth of natural resources and innovative potential create a unique foundation for growth. Our partnership with SIGMA reflects KRTL’s commitment to fostering sustainable development and advancing access to healthcare solutions worldwide.” The FDA registration underscores KRTL’s dedication to regulatory excellence and SIGMA’s commitment to quality manufacturing. Together, the companies are poised to introduce Bolivian ingenuity to international markets, setting a precedent for the future of Bolivia’s pharmaceutical exports and demonstrating the global value...